BWM
NBIX icon

Bullock Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Bullock Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-68
Closed -$8.7K – 648
2025
Q2 		$8.7K Hold
68
– – ﹤0.01% 408
2025
Q1 		$7.28K Hold
68
– – ﹤0.01% 419
2024
Q4 		$9.28K Hold
68
– – 0.01% 400
2024
Q3 		$7.76K Buy
+68
New +$9.32K ﹤0.01% 402
2024
Q2 		– Sell
-134
Closed -$18.9K – 586
2024
Q1 		$18.9K Buy
+134
New +$18.3K 0.01% 308

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bullock Wealth Management's NBIX Position: Q3 2025 in Review

Bullock Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 68 shares — an estimated $8.7K sold.

Bullock Wealth Management first reported a position in NBIX in Q1 2024 and held it in 5 quarters. The position peaked at $18.9K in Q1 2024. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Bullock Wealth Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Bullock Wealth Management sold 68 Neurocrine Biosciences shares in Q3 2025, an estimated $8.7K.
  • Bullock Wealth Management first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 5 quarters.
  • Bullock Wealth Management's Neurocrine Biosciences position peaked at $18.9K in Q1 2024.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Bullock Wealth Management's 13F filing for Q3 2025, filed 24 Sep 2026.